Responses

PDF

Naoxuekang, Xinnaoshutong and Xuesaitong capsules for treating stroke: a protocol for a randomised controlled trial
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

PLEASE NOTE:

  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

  • Published on:
    Role of Ethical and Legal Funding Implications’ from Funding Agencies
    • Atif A Baig, Medical Researcher Faculty of Medicine. Universiti Sultan Zainal Abidin, Malaysia

    Dear Editor of BMJ.

    I was reading it all and I assume that many times the issues can’t be ethical but are still legal. Being a neutral moiety, I assume just based on a fact to get justification from author or anyone sending a response is not enough for such serious ethical concerns. There is a serious need to look into the legal implications of use of funding. As per usual practice, the report of all grants are submitted to the funding bodies and if the “authors” have explained and mentioned the use of this all funding or “left over funding” in specific time to be used later as per rules and regulations, there must be no issue as far as no “conflict of interest “ is there between the authors and the funding agency. Seems it’s a very minor issue but for me it’s a new issue of its type and thank you for a very positive attitude from BMJ Open editor for facilitating science and honesty not in science but the concern minor issues.

    Conflict of Interest:
    None declared.
  • Published on:
    Note from the Editor in reference to response from Yuzhen Li

    The editorial team of BMJ Open are currently investigating the issues raised by Yuzhen Li in response to this article.

    We have asked the authors to respond to the points raised and will investigate the case in line with the principles of the Committee On Publication Ethics (COPE).

    Conflict of Interest:
    I am the Editor of BMJ Open.
  • Published on:
    The fund supports of article e015983 and ChiCTR-IOR-1701039 result in ethical issues and academic misconducts.
    • Yuzhen Li, Pharmacy manager yuzhenli@yandex.com

    Dear editorial board of BMJ Open,

    In article e015983, http://bmjopen.bmj.com/content/7/11/e015983, and registration information, http://www.chictr.org.cn/showprojen.aspx?proj=17715, of its RCT, it was claimed that this RCT, ChiCTR-IOR-1701039, is running and funded by 3 projects of National Natural Science Foundation of China, namely 81202849, 30600834 and 81603659.

    However, none of these three projects could fund this RCT. The first project has been closed in 2015, see http://npd.nsfc.gov.cn/projectDetail.action?pid=81202849. The second project also has been closed in 2009, see http://npd.nsfc.gov.cn/projectDetail.action?pid=30600834. But the RCT in article e015983 is running from 2017-1-1 to 2018-1-1. Time difference results in that the first 2 projects were impossible to fund this RCT.

    The third project is only one project listed which could fund this RCT because it is to be implemented from 2016 to 2018. But content of project 81603659 is prevention and treatment of cognitive impairment in epileptic rats, not a human RCT. Although the content of project 81603659 is still not revealed, this fact can be confirmed on web site of National Natural Science Foundation of China,...

    Show More
    Conflict of Interest:
    Several of the drugs mentioned in the article are sold in our pharmacy, I am not sure whether this is a conflict of interest.